The article was published in the Journal of Cellular Biochemistry in January 2018. The authors of the manuscript are N. Sobhani, G. Roviello, S.P. Corona, M. Scaltriti, A. Ianza, M. Bortul, F. Zanconati, and D. Generali.

The article discusses the importance of reliable biomarkers in determining the response and resistance of breast cancer patients to treatment. Specifically, it focuses on the mutational status of the PI3K (Phosphatidylinositol 3-kinase) gene as a prognostic factor and predictor of response to anti-cancer treatments. The meta-analysis included 1929 cases from randomized clinical trials and confirmed that the presence of a PIK3CA mutation is an independent negative prognostic factor in breast cancer.

The authors highlight the need for further investigation into potential biomarkers that can predict the likelihood of response to specific anti-PI3K/mTOR, anti-HER2, and other targeted therapies. The aim is to improve the selection of patients who are most likely to benefit from these treatments. The manuscript emphasizes the importance of personalized medicine and the use of molecular diagnosis to tailor treatments for breast cancer patients.

Please note that the content of the manuscript is truncated, and further details are not available in the provided excerpt.